During the last decade, it has become apparent that baculoviruses not only represent a powerful expression system for production of recombinant proteins in insect cells but also can be used for transduction of dividing and nondividing mammalian cells and tissues in vitro, ex vivo, and in vivo (49). Advantages of the use of baculoviruses as gene delivery agents include their inability to replicate in mammalian cells, apparent lack of cytotoxicity, capacity to sustain large insertions of foreign DNA, ability to target many different cell types, and superior safety features relative to mammalian virus-based transduction systems (25,37,38,48). Thus, increasing interest for the development of recombinant baculoviruses as gene delivery vectors for use in human gene therapy exists.All baculovirus vectors for gene delivery in mammalian cells reported thus far have been based on the Autographa californica nuclear polyhedrosis virus (AcNPV). This is primarily due to the relatively wide host range of the virus and the multiplicity of lepidopteran cell lines in which it can be grown and propagated effectively as well as the availability of integrated methodologies allowing the rapid generation of recombinant viruses (55, 80). In contrast, there is a paucity of information regarding the suitability of other baculovirus species, particularly species with narrow host ranges to function as transduction vectors for mammalian cells.In this regard, it is also known that AcNPV has a propensity to express endogenous viral genes in nonhost insect species (12, 13). Moreover, studies involving transfection of mammalian cells with gene constructs employing baculovirus gene promoter elements have shown that certain early baculovirus promoters are marginally functional in mammalian cells and can also be activated by mammalian virus regulators (46, 66). These findings raise safety concerns related to the potential for low-level baculovirus gene expression in mammalian cells and the triggering of cellular immune responses against the transduced cells by the recipient host (61).In this work, we have explored the capacity of Bombyx mori NPV (BmNPV), the second best characterized baculovirus species after AcNPV (2,20,21,27,40,56,57,65), which has a very limited host range (58), to function as a transducing vector for mammalian cell lines and primary Schwann cells. The choice for the latter rests with the results of experimental transplantation in rodent and primate models, which has provided substantial evidence that Schwann cells are good candidates for cell therapy in human central nervous system (CNS) demyelinating diseases, such as multiple sclerosis, and trauma (5,6,9,19,26). Schwann cells provide trophic support and remyelinate demyelinated CNS axons. However, their integration in the CNS is limited. Therefore, modifying Schwann cells to express "therapeutic" factors enhancing axonal regeneration and remyelination by ex vivo gene transduction is a promising strategy to improve their capacity to repair the injured or demyelinated nervous ...